SCOPE Community E-meeting: Developments in PrEP implementation issues

Implementation Plan for the Introduction of the PrEP Ring and Long-acting Injectable Cabotegravir for HIV Prevention – Eswatini, August 2024

Initiation and Continued Use of Oral Pre-Exposure Prophylaxis among Pregnant and Postpartum Women in South Africa (PrEP-PP): A demonstration cohort study

This article from The Lancet HIV describes the results of a demonstration study in South Africa, PrEP-PP, to integrate oral PrEP provision into public clinics offering antenatal and postnatal care to pregnant and lactating people.

Acceptability of Six-Monthly PrEP Dispensing Supported with Interim HIV Self-Testing to Simplify PrEP Delivery in Kenya: Findings from qualitative research

This article from BMC Health Services Research discusses the results of a pilot in Kenya to explore the acceptability of dispensing PrEP twice a year, with interim HIV self-testing, versus quarterly, with clinic-based HIV testing.

CAB PrEP Introduction Situation Analysis – South Africa – 2024

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform.

Dynamic Choice HIV Prevention with Cabotegravir Long-acting Injectable in Rural Uganda and Kenya: A randomised trial extension

This article from The Lancet HIV discusses the results of the SEARCH dynamic choice study conducted in Kenya and Uganda, comparing outcomes between one group offered a choice between oral PrEP, post-exposure prophylaxis, and cabotegravir for PrEP, and a second group receiving the standard of care.

Adolescent Girls and Young Women Overcoming Adherence Challenges with Vaginal and Oral PrEP Use: A longitudinal qualitative study from a crossover trial in South Africa, Uganda, and Zimbabwe

This article from AIDS and Behavior explores South African, Ugandan, and Zimbabwean adolescent girls and young women’s experiences in a crossover trial of two HIV prevention products: daily oral PrEP and a monthly dapivirine vaginal ring.

Dapivirine Vaginal Ring Early Market Access Vehicle (EMAV)

In response to the voices of adolescent girls and women who need more HIV prevention choices, The Global Fund (GF) and the Children Investment Fund Foundation (CIFF) have partnered to make dapivirine vaginal rings available in GF-supported countries through an early market access vehicle. See below for EMAV request forms. For guidance on how to…

Access Workbook for Cabotegravir for PrEP, Dapivirine Vaginal Ring, and Lenacapavir for PrEP

This workbook, compiled by the Global Fund, contains key access information relating to cabotegravir (CAB) for PrEP, the dapivirine vaginal ring (DVR), and lenacapavir (LEN) for PrEP for all lower and middle income countries, including eligibility for Global Fund support, PEPFAR support status, regulatory status of CAB for PrEP and the DVR, access to non-profit…

PrEP Ring Instructional Video

The PrEP Ring is a long-acting vaginal ring that a woman can use to reduce the risk of HIV transmission during vaginal sex. Women urgently need options for HIV prevention, so that they can choose that best meets their needs and circumstances. Please click on the video link(s) below to see How to Use the…

Expanding Access to Lenacapavir

This United Advocates Network Call, titled Breaking New Ground: Expanding Access to Lenacapavir— Lessons from Dolutegravir and the Future of HIV Prevention, brought together global health experts, community advocates, and civil society organizations to discuss the challenges and opportunities in ensuring equitable access to Lenacapavir.